Levodopa/Carbidopa
- Generic Name
- Levodopa/Carbidopa
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 82
- Registration Number
- NCT01519284
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Augmenting Language Therapy for Aphasia: Levodopa
- Conditions
- Nonfluent AphasiaStroke
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 36
- Registration Number
- NCT01429077
- Locations
- 🇺🇸
Center for Aphasia Research & Treatment, Chicago, Illinois, United States
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01411137
- Locations
- 🇺🇸
The Parkinson's Institute, Sunnyvale, California, United States
🇺🇸University of Nevada School of Medicine, Las Vegas, Nevada, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Long Island, Commack, New York, United States
Cognitive Remediation for Cocaine Dependence
- Conditions
- Cocaine Dependence
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-03-29
- Target Recruit Count
- 119
- Registration Number
- NCT01393457
- Locations
- 🇺🇸
Behavioral and Biomedical Sciences Building, Houston, Texas, United States
Levodopa for the Treatment of Residual Amblyopia
- Conditions
- Amblyopia
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 139
- Registration Number
- NCT01190813
- Locations
- 🇺🇸
Wilmer Eye Institute, Baltimore, Maryland, United States
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT01130493
- Locations
- 🇺🇸
Margolin Brain Institute, Fresno, California, United States
🇺🇸Charlotte Neurological Services, Port Charlotte, Florida, United States
🇺🇸UM Movement Disorders Center, Miami, Florida, United States
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 471
- Registration Number
- NCT00974974
- Locations
- 🇺🇸
Investigator 7, Little Rock, Arkansas, United States
🇺🇸Investigator 64, Bradenton, Florida, United States
🇺🇸Investigator 4, Saint Petersburg, Florida, United States
Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Intec Pharma Ltd.
- Registration Number
- NCT00947037
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Wolfson Medical Center, Holon, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2010-01-18
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 10
- Registration Number
- NCT00906828
- Locations
- 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 5
- Registration Number
- NCT00888186
- Locations
- 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.